BioNotebook: Xencor regains rights from Amgen; plus three other deals

 
• By Mandy Jackson

Xencor gains greater control in Amgen pact; Zogenix buys Brabant Pharma; CTI BioPharma buys worldwide rights to tosedostat; and Takeda licenses Mersana ADC.

More from Alimentary/Metabolic

More from Therapy Areas